Alec Machiels J.D., MBA
Net Worth

Last updated:

What is Alec Machiels J.D., MBA net worth?

The estimated net worth of Mr. Alec Machiels J.D., MBA is at least $9,310,418 as of 21 Jul 2023. He owns shares worth $7,124,603 as insider, has earned $1,848,315 from insider trading and has received compensation worth at least $337,500 in Apellis Pharmaceuticals, Inc..

What is the salary of Alec Machiels J.D., MBA?

Mr. Alec Machiels J.D., MBA salary is $67,500 per year as Co-Founder & Independent Director in Apellis Pharmaceuticals, Inc..

How old is Alec Machiels J.D., MBA?

Mr. Alec Machiels J.D., MBA is 52 years old, born in 1973.

What stocks does Alec Machiels J.D., MBA currently own?

As insider, Mr. Alec Machiels J.D., MBA owns shares in one company:

Company Title Shares Price per share Total value
Apellis Pharmaceuticals, Inc. (APLS) Co-Founder & Independent Director 267,641 $26.62 $7,124,603

What does Apellis Pharmaceuticals, Inc. do?

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS logo
APLS
Apellis Pharmaceuticals, Inc.
$26.62

Alec Machiels J.D., MBA insider trading

Apellis Pharmaceuticals, Inc.

Mr. Alec Machiels J.D., MBA has made 40 insider trades between 2020-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 50,000 units of APLS stock on 20 Jul 2023. As of 21 Jul 2023 he still owns at least 267,641 units of APLS stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 49,779 $2.67 $132,910
Option
Common Stock 49,779 $2.67 $132,910
Option
Stock Option (Right to Buy) 50,000 $2.67 $133,500
Option
Common Stock 50,000 $2.67 $133,500
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $64.79 $80,988
Sale
Common Stock 1,250 $88.41 $110,513
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $88.66 $110,825
Option
Common Stock 1,250 $2.67 $3,338
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $81.05 $101,313
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $64.03 $80,038
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $52.38 $65,475
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $52.42 $65,525
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $52.35 $65,438
Option
Common Stock 1,250 $2.67 $3,338
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $48.01 $60,013
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $59.31 $74,138
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $66 $82,500
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $67.21 $84,012
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $46.33 $57,913
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $39.29 $49,113
Option
Common Stock 1,250 $2.67 $3,338
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $39.18 $48,975
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $50.9 $63,625
Option
Common Stock 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $39.57 $49,463
Option
Stock option (right to buy) 1,250 $2.67 $3,338
Sale
Common Stock 1,250 $45.43 $56,788
Option
Stock Option (Right to Buy) 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Option
Common Stock 1,250 $2.67 $3,338
Option
Stock Option(Right to Buy) 1,250 $2.67 $3,339
Sale
Common Stock 1,250 $40.56 $50,700
Option
Common Stock 3,000 $2.67 $8,010
Sale
Common Stock 3,000 $42.88 $128,640
Option
Stock Option (Right to Buy) 3,000 $2.67 $8,010
Option
Stock Option (Right to Buy) 6,000 $2.67 $16,020
Sale
Common Stock 3,000 $43.5 $130,500
Option
Common Stock 3,000 $2.67 $8,010
Option
Common Stock 3,000 $2.67 $8,010
Sale
Common Stock 3,000 $35 $105,000
Sale
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Sale
Common Stock 2,500 N/A N/A
Option
Stock Option (Right to Buy) 2,500 N/A N/A
Option
Common Stock 2,500 N/A N/A
Sale
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 7,500 $2.67 $20,025
Sale
Common Stock 7,500 $2.67 $20,025
Option
Stock Option (Right to Buy) 7,500 $2.67 $20,025
Option
Common Stock 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Stock Option (Right to Buy) 2,500 $2.67 $6,675
Option
Common Stock 2,500 $2.67 $6,675
Sale
Common Stock 2,500 $2.67 $6,675

Apellis Pharmaceuticals key executives

Apellis Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: